Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
Clinical Trial
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
A phase II trial that used a regimen of interleukin-2 (IL-2) and interferon alfa-2a (IFN-alpha) was undertaken to evaluate the efficacy of this combination in the treatment of metastatic renal cell carcinoma. ⋯ In view of the minimal antitumor activity and associated toxicity, the combination of IL-2 and IFN-alpha in this trial cannot be recommended. The investigation of new cytokines and the identification of biologic prognostic factors for a response to immunologic therapy are essential.